Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy for SLCA is directed to recovering the function of the affected organs by targeting the abnormal plasma cell clone and slowing deposition of amyloid fibrils. The NCCN Guidelines for SLCA provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated SLCA.
|Original language||English (US)|
|Number of pages||15|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - Jan 2023|
ASJC Scopus subject areas